Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy

Brain

Volumn 129, Issue 5, 2006, Pages 1281-1292

  Thomas, Pierre ^a   Valton, Luc ^b   Genton, Pierre ^c  

^a PASTEUR HOSPITAL   (France)

^b CHU RANGUEIL   (France)

^c CENTRE SAINT PAUL   (France)

Author keywords

Adverse effects; Antiepileptic drugs; Epilepsy prognosis; Status epilepticus

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GABAPENTIN; PHENOBARBITAL; PHENYTOIN; VIGABATRIN;

ABSENCE; ADOLESCENT; ADULT; ANTICONVULSANT THERAPY; ARTICLE; CHILDHOOD ABSENCE EPILEPSY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE REDUCTION; ELECTROENCEPHALOGRAM; EPILEPSY WITH GRAND MAL ON AWAKENING; EPILEPTIC STATE; FEMALE; GENERALIZED EPILEPSY; HUMAN; LONG TERM CARE; MALE; MYOCLONUS EPILEPSY; PHARMACODYNAMICS; PRIORITY JOURNAL; SEIZURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTICONVULSANTS; CARBAMAZEPINE; DRUG ADMINISTRATION SCHEDULE; ELECTROENCEPHALOGRAPHY; EPILEPSY; EPILEPSY, ABSENCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; STATUS EPILEPTICUS;

EID: 33646258732     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awl047     Document Type: Article

References (54)

1. Agathonikou A, Panayiotopoulos CP, Giannakodimos S, Koutroumanidis M. Typical absence status in adults: diagnostic and syndromic considerations. Epilepsia 1998; 39: 1265-76.
2. Aguglia U, Zappia M, Quattrone A. Carbamazepine-induced nonepileptic myoclonus in a child with benign epilepsy. Epilepsia 1987; 28: 515-8.
3. Asconape J, Diedrich A, DellaBadia J. Myoclonus associated with the use of gabapentin. Epilepsia 2000; 41: 479-81.
4. Bauer J. Seizure-inducing effects of antiepileptic drugs: a review. [Review]. Acta Neurol Scand 1996; 94: 367-77.
5. Benbadis SR, Tatum WO, Gieron M. Idiopathic generalized epilepsy and choice of antiepileptic drugs. Neurology 2003; 61: 1793-5.
6. Berkovic SF. Aggravation of generalized epilepsies. [Review]. Epilepsia 1998; 39 (Suppl 3): S11-S14.
7. Biraben A, Allain H, Scarabin JM, Schuck S, Edan G. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology 2000; 55: 1758.
8. Bureau M, Tassinari CA. The syndrome of myoclonic absences. In: Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P, editors. Epileptic syndromes in infancy, childhood and adolescence. 4th edn. Montrouge: John Libbey Eurotext; 2005. p. 337-44.
9. Callahan DJ, Noetzel MJ. Prolonged absence status epilepticus associated with carbamazepine therapy, increased intracranial pressure and transient MRI abnormalities. Neurology 1992; 42: 2198-201.
10. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989; 30: 389-99.
11. Corda D, Gelisse P, Genton P, Dravet C, Baldy-Moulinier M. Incidence of drug-induced aggravation in benign epilepsy with centrotemporal spikes. Epilepsia 2001; 42: 754-9.
12. Crespel A, Genton P, Berramdane M, Coubes P, Monicard C, Baldy-Moulinier M, et al. Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies. Neurology 2005; 65: 762-4.
13. Defazio G, Livrea P, Lamberti P, De Salvia R, Laddomada G, Giorelli M, et al. Isolated so-called apraxia of eyelid opening: report of 10 cases and a review of the literature. Eur Neurol 1998; 39: 204-10.
14. Dhuna A, Pascual-Leone A, Talwar D. Exacerbation of partial seizures and onset of nonepileptic myoclonus with carbamazepine. Epilepsia 1991; 32: 275-8.
15. Gastaut H. Classification of status epilepticus. In: Delgado-Escueta AV, Wasterlain CG, Treiman DM, Porter RJ, editors. Status epilepticus. Advances in neurology, Volume 34. New York: Raven Press; 1983. p. 83-92.
16. Gelisse P, Genton P, Raybaud C, Thomas P, Dravet C. Structural brain lesions do not influence the prognosis of juvenile myoclonic epilepsy. Acta Neurol Scand 2000; 102: 188-91.
17. Gelisse P, Genton P, Kuate C, Pesenti A, Baldy-Moulinier M, Crespel A. Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies. Epilepsia 2004; 45: 1282-6.
18. Genton P, McMenamin J. Aggravation of seizures by antiepileptic drugs: what to do in clinical practice. [Review]. Epilepsia 1998; 39 (Suppl 3): S26-S29.
19. Genton P, Gonzalez-Sanchez MSE, Saltarelli A, Bureau M, Dravet C, Roger J. Misleading aspects of the standard electroencephalogram in juvenile myoclonic epilepsy: a retrospective study of 56 consecutive cases. Neurophysiol Clin 1995; 25: 283-90.
20. Genton P, Gelisse P, Thomas P, Dravet C. Do carbamazepine and phenytoin aggravate juvenile myoclonic epilepsy? Neurology 2000; 55: 1106-9.
21. Guerrini R, Belmonte A, Genton P. Antiepileptic drug-induced worsening of seizures in children. Epilepsia 1998; 39 (Suppl 3): S2-S10.
22. Kaplan PW. Behavioral manifestations of nonconvulsive status epilepticus. Epilepsy Behav 2002; 3: 122-39.
23. Lancman ME, Asconape JJ, Penry JK. Clinical and EEG asymmetries in juvenile myoclonic epilepsy. Epilepsia 1994; 35: 302-6.
24. Lerman P. Seizures induced or aggravated by anticonvulsants. Epilepsia 1986; 27: 706-10.
25. Lerman-Sagie T, Watemberg N, Kramer U, Shahar E, Lerman P. Absence seizures aggravated by valproic acid. Epilepsia 2001; 42: 941-3.
26. Levy LL, Fenichel GM. Diphenylhydantoin-activated seizures. Neurology 1965; 15: 716-22.
27. Liporace JD, Sperling MR, Dichter MA. Absence seizures and carbamazepine in adults. Epilepsia 1994; 35: 1026-8.
28. Liu Z, Vergnes M, Depaulis A, Marescaux C. Involvement of intrathalamic GABA-B neurotransmission in the control of absence seizures in the rat. Neuroscience 1992; 48: 87-93.
29. Marescaux C, Vergnes M, Depaulis A. Genetic absence epilepsy in rats from Strasbourg - a review. [Review]. J Neural Transm Suppl 1992; 35: 37-69.
30. McCormick DA. Cortical and subcortical generators of normal and abnormal rhythmicity. [Review]. Int Rev Neurobiol 2002; 49: 99-114.
31. McLean MJ, Macdonald RL. Carbamazepine and 10,11-epoxycarbamazepine produce use- and voltage-dependent limitation of rapidly firing action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 1986; 238: 727-38.
32. Michelucci R, Tassinari CA. Response to vigabatrin in relation to seizure type. Br J Clin Pharmacol 1989; 27 (Suppl 1): S119-S24.
33. Michelucci R, Rubboli G, Passarelli D, Riguzzi P, Volpi L, Parmeggiani L, et al. Electroclinical features of idiopathic generalised epilepsy with persisting absences in adult life. J Neurol Neurosurg Psychiatry 1996; 61: 471-7.
34. Montalenti E, Imperiale D, Rovera A, Bergamasco B, Benna P. Clinical features, EEG findings and diagnostic pitfalls in juvenile myoclonic epilepsy: a series of 63 patients. J Neurol Sci 2001; 184: 65-70.
35. Nanba Y, Maegaki Y. Epileptic negative myoclonus induced by carbamazepine in a child with BECTS. Pediatr Neurol 1999; 21: 664-7.
36. Osorio I, Reed RC, Peltzer JN. Refractory idiopathic absence status epilepticus: a probable paradoxical effect of phenytoin and carbamazepine. Epilepsia 2000; 41: 887-94.
37. Panayiotopoulos CP, Agathonikou A, Ahmed-Sharoqi I, Parker APJ. Vigabatrin aggravates absences and absence status. Neurology 1997a; 49: 1467.
38. Panayiotopoulos CP, Koutroumanidis M, Giannakodimos S, Agathonikou A. Idiopathic generalised epilepsy in adults manifested by phantom absences, generalised tonic-clonic seizures, and frequent absence status. J Neurol Neurosurg Psychiatry 1997b; 63: 622-7.
39. Parker AP, Agathonikou A, Robinson RO, Panayiotopoulos CP. Inappropriate use of carbamazepine and vigabatrin in typical absence seizures. Dev Med Child Neurol 1998; 40: 517-9.
40. Parmeggiani A, Fraticelli E, Rossi PG. Exacerbation of epileptic seizures by carbamazepine: report of 10 cases. Seizure 1998; 7: 479-83.
41. Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. [Review]. Epilepsia 1998; 39: 5-17.
42. Sazgar M, Bourgeois BF. Aggravation of epilepsy by antiepileptic drugs. [Review]. Pediatr Neurol 2005; 33: 227-34.
43. Shields WD, Saslow E. Myoclonic, atonic and absence seizures following institution of carbamazepine therapy in children. Neurology 1983; 33: 1487-9.
44. Shirasaka Y, Mitsuyoshi I. A case of epileptic negative myoclonus: therapeutic considerations. Brain Dev 1999; 21: 209-12.
45. Shorvon S. Status epilepticus, its clinical features and treatment in children and adults. Cambridge: Cambridge University Press; 1994.
46. Snead OC. Antiabsence activity of specific GABA-B and γ-hydroxybutyric acid antagonists. Pharmacol Biochem Behav 1996; 53: 73-80.
47. Snead OC, Hosey LC. Exacerbation of seizures in children by carbamazepine. N Engl J Med 1985; 313: 916-21.
48. So E, Ruggles K, Cascino G, Ahmann P, Weatherford K. Seizure exacerbation and status epilepticus related to carbamazepine-10,11-epoxide. Ann Neurol 1994; 35: 743-6.
49. Talwar D, Arora MSE, Sher PK. EEG changes and seizures exacerbation in young children treated with carbamazepine. Epilepsia 1994; 35: 1154-9.
50. Tassinari CA, Rubboli G, Gardella E. Negative myoclonus. Clin Neurosci 1995; 3: 209-13.
51. Thomas P, Genton P, Gelisse P, Wolf P. Juvenile myoclonic epilepsy. In: Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P, editors. Epileptic syndromes in infancy, childhood and adolescence. 4th edn. Montrouge: John Libbey Eurotext; 2005. p. 361-82.
52. Trinka E, Dilitz E, Unterberger I, Luef G, Deisenhammer F, Niedermuller U, et al. Non convulsive status epilepticus after replacement of valproate with lamotrigine. J Neurol 2002; 249: 1417-22.
53. Usui N, Kotagal P, Matsumoto R, Kellinghaus C, Luders HO. Focal semiologic and electroencephalographic features in patients with juvenile myoclonic epilepsy. Epilepsia 2005; 46: 1668-76.
54. Yang MT, Lee WT, Chu LW, Shen YZ. Anti-epileptic drugs-induced de novo absence seizures. Brain Dev 2003; 25: 51-6.